Pharmaceutical Technology1 小时
Calquence by AstraZeneca for Graft Versus Host Disease (GVHD): Likelihood of Approval
Calquence is under clinical development by AstraZeneca and currently in Phase II for Graft Versus Host Disease (GVHD).
Pharmaceutical Technology2 小时
Calquence by AstraZeneca for Follicular Lymphoma: Likelihood of Approval
Calquence is under clinical development by AstraZeneca and currently in Phase III for Follicular Lymphoma. According to GlobalData, Phase III drugs for Follicular Lymphoma have a 55% phase transition ...